Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Nov 04, 2021 9:57am
205 Views
Post# 34086148

RE:RE:People forget Dr. Kellum was heavily involved in FDA phase 3

RE:RE:People forget Dr. Kellum was heavily involved in FDA phase 3Correction (my apologies)

"At least some of us are able to counter the dilution with 25-35% discounts off financing levels, 40-50% discounts off warrant exercise and new warrant issuance levels, and 2/3rd discounts off spring 2021 levels. All with no discernible changes to the LT potential ( IMHO)"

Actually the Real World Evidence that is starting to accumulate on the possible benefit of using PMX-HP Covid patients, and the recent acknowledgement of Kellum of that fact (in discussion with Ronco), suggest to me, at least, that there may in fact be a material increase in long term revenue potential slowly coming to light (under the assumption that  the FDA approves PMX, and the incidence of Septic Shock is likely on the rise due to Covid).  Not to mention AKI, and as a consequence the need for more equipment in hospitals, and as another consequence, the need for more Home Dialysis equipment in the future.  (See my Covid/PMX post with many medical study references as it relates to PMX and Covid - including one from Ronco himself)

So I have actually raised my upside target potential, in the past 6 months...despite some annoying delays on deliverables that were promised by our CEO feller.   Still disappointed that the Company doesn't seem to want to talk about it to the investment community though (Bazinga was kinda weak IMO), especially state-side (where all the demand side is, and where the vast majority of the LT revenues will be generated)

MM


<< Previous
Bullboard Posts
Next >>